The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.
Haverkamp
W
W
Breithardt
G
G
Camm
A J
AJ
Janse
M J
MJ
Rosen
M R
MR
Antzelevitch
C
C
Escande
D
D
Franz
M
M
Malik
M
M
Moss
A
A
Shah
R
R
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002309:Cardiology; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004562:Electrocardiography / Q000187:drug effects*; D005060:Europe; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D009206:Myocardium / Q000378:metabolism; D011050:Policy Making; D017410:Practice Guidelines as Topic; D012955:Societies, Medical; D014665:Vasodilator Agents / Q000009:adverse effects*
D000889:Anti-Arrhythmia Agents; D000893:Anti-Inflammatory Agents; D014150:Antipsychotic Agents; D014665:Vasodilator Agents